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Orally disintegrating systems have carved a niche amongst the oral drug delivery systems due to the 
highest compliance of the patients, especially the geriatrics and pediatrics. In addition, patients suffering 
from dysphagia, motion sickness, repeated emesis and mental disorders prefer these medications because 
they cannot swallow large quantity of water. Further, drugs exhibiting satisfactory absorption from the 
oral mucosa or intended for immediate pharmacological action can be advantageously formulated in 
these dosage forms. However, the requirements of formulating these dosage forms with mechanical 
strength sufficient to withstand the rigors of handling and capable of disintegrating within a few seconds 
on contact with saliva are inextricable. The purpose of this research was to mask the bitter taste of 
granisetron hydrochloride. To mask the taste Kollicoat® Smartseal 30D was used as coating polymer for 
pellet coating. The coated pellets of the drug was directly compressed with different superdisintegrant 
as AC-Di-Sol, Explotab and Kollidon CL in different concentration 5.0-7.5% w/w into an ODT. The 
prepared tablets were evaluated for hardness, friability, weight variation, wetting time, wet absorption 
ratio, in-vitro disintegration time and in vitro dissolution studies. Tablets exhibited quick disintegration 
characteristics with Kollidon CL in concentration 7.5% w/w i.e., within 20 seconds, which is characteristic 
of orally disintegrating dosage forms. More than 98% of drug was released from the formulations within 
15 minutes. Formulations subjected to stability testing as per the ICH guidelines for 3 months, indicated 
stability with no change in taste, hardness, drug content, disintegration time and dissolution profiles. 
Thus, the results conclusively demonstrated successful masking of taste and rapid disintegration of the 
formulated dosage forms in the oral cavity.
Uniterms: Granisetron hydrochloride/taste masking. Oro Dispersible Tablet (ODT). Pellets/coating. 
Oral drugs/delivery system.
Sistemas de desintegração oral têm um nicho entre os sistemas de administração de medicamentos por 
via oral devido à maior aceitação dos pacientes, especialmente os de geriatria e pediatria. Além disso, 
pacientes que sofrem de disfagia, enjoo de movimento, emese repetida e distúrbios mentais preferem 
estes medicamentos porque não podem engolir grande quantidade de água. Além disso, os fármacos que 
exibem absorção satisfatória a partir da mucosa oral ou que se destinam a ação farmacológica imediata 
podem ser vantajosamente formulados nestas formas de dosagem. No entanto, a formulação destas 
formas farmacêuticas exige-lhes resistência mecânica suficiente para suportar os rigores do manuseio e 
capacidade de desintegrar dentro de alguns segundos em contato com a saliva. O objetivo desta pesquisa 
foi o de mascarar o gosto amargo de cloridrato de granisetrona. Para mascarar o sabor, utilizou-se  
Kollicoat smartseal 30D como polímero para io revestimento dos péletes. Os péletes revestidos do 
fármaco foram diretamente comprimidos com superdesintegrante diferente como Ac-Di-Sol, Explotab 
e Kollidon CL, em diferentes concentrações 5.0-7.5% m/m em comprimidos de dispersão oral (ODT). 
Os comprimidos preparados foram avaliados quanto à dureza, friabilidade, variação de peso, ao tempo 
de umedecimento, à razão de absorção de umidade, ao tempo de desintegração in vitro e em estudos de 
dissolução in vitro. Os comprimidos apresentaram características de desintegração rápida com Kollidon 
CL, em concentração de 7,5% m/m, ou seja, dentro de 20 segundos, o que é característico para formas 
farmacêuticas de desintegração oral. Mais do que 98% do fármaco foi liberado a partir das formulações 
no prazo de 15 minutos. Formulações submetidas a testes de estabilidade de acordo com as diretrizes 
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da ICH por 3 meses indicaram estabilidade sem alteração no sabor, dureza, teor de fármaco, tempo de 
desintegração e perfis de dissolução. Assim, os resultados demonstraram que o mascaramento de gosto 
foi bem-sucedido e atingiu-se rápida desintegração das formas de dosagem na cavidade oral.
Unitermos: Cloridrato granisetrona/mascaramento de sabor. Comprimidos de Dispersão Oral. Grânulos/
revestimento. Medicamentos de via oral/sistemas de administração.
INTRODUCTION
Orally disintegrating tablets also called as fast 
dissolving or mouth dissolving tablets are such kind of 
dosage forms which when placed in mouth disintegrate 
rapidly in a matter of seconds. They are different from 
lozenges or buccal tablets which require more than a 
minute to get dissolved in mouth (William, Tapash, 
2005). Any dosage form or a novel drug delivery system 
which improves patient compliance is of great interest to 
scientists in which orally disintegrating tablets stands first 
among them. Market studies indicated that 70% of the 
population ask their doctors or prefer to purchase orally 
disintegrating tablets over conventional tablets or liquids 
(William, Tapash, 2005). They are more advantageous in 
case of geriatric or paediatric patients who feel difficulty 
in swallowing tablets or capsules. They are also useful in 
disease conditions like motion sickness, repeated emesis 
or coughing where it is difficult to swallow tablet (William, 
Tapash, 2005). A vast variety of pharmaceutical research 
is directed at developing new dosage forms. Most of these 
efforts have focused on either formulating novel drug 
delivery systems or increasing the patient compliance. 
Among the dosage forms developed for facilitating ease 
of medication, the orally disintegrating systems have been 
the favorite of product development scientists.
The strategy of compressing multiparticulates into 
an orally disintegrating tablet is of more interest due 
to its ease in technology and cost effectiveness. Taste 
masking is of prime importance in formulating an orally 
disintegrating tablet. One of the applications of coating 
of multiparticulate is taste masking (Honey et al., 2008). 
Multiparticulate or pellets can be compressed into a tablet 
that can disintegrate in less than a minute (Honey et al., 
2008). The concept of orally disintegrating dosage forms 
has emerged from the desire to provide patients with 
more conventional means of taking their medication. 
Interestingly, the demand for ODT has enormously 
increased during the last decade, particularly for geriatric 
and paediatric patients who experience difficulty in 
swallowing conventional tablets and capsules. Hence, 
they do not comply with prescription, which results in 
high incidence of ineffective therapy (Seager, 1998). 
In disease conditions such as motion sickness, sudden 
episodes of attacks of coughing and repeated emesis 
swallowing conventional tablets become difficult. Orally 
disintegrating dosage forms can serve as an effective 
alternative mode of drug delivery in such situations. 
When put in the mouth, these dosage forms disintegrate 
instantly to release the drug, which dissolves or disperses 
in the saliva. Thereafter, the drug may get absorbed from 
the pharynx and oesophagus or from other sections of 
gastrointestinal tract as the saliva travels down. In such 
cases, bioavailability is significantly greater than that 
observed from conventional tablet dosage form (Dobetti, 
2001, Ghosh, 2005). Hence, orally disintegrating systems 
may be anticipated to result in achievement of the required 
peak plasma concentration rapidly for drugs unstable in 
the gastric pH.
Taste is a perception on which lies the fate of oral 
pharmaceuticals. Administration of bitter drugs orally 
with acceptable level of palatability is a key issue for 
health care providers, especially for paediatric patients 
(Patel, Prajapati, Raval, 2010). Though adults might think 
that bitter tasting medicine work better, this is not the 
case for children (Matsui, 2007). Children might refuse 
to take their medication completely due to taste issues 
(Shishu, Kashyap, 2008). Pharmaceutical manufacturers 
of pediatric medicine need to be aware of children’s taste 
preferences, as the product taste will greatly affect the 
child’s willingness to take the medication repeatedly. 
Various chemical and physical methods are involved 
in taste masking, which prevent the drug substance 
from interacting with taste buds. The simplest method 
involves use of flavour enhancers (Reddy et al., 2010). 
A well-constructed flavour system is crucial to mask or 
hide any medicinal tastes for oral drug formulations, 
because it influences patient acceptability and compliance 
and thereby makes the product more tolerable. Children 
generally prefer sweet preparations with fruity flavours. 
Flavouring agents are generally present in amounts 
of from about 0.01 to about 5%. Examples of suitable 
flavouring agents include cherry flavour, orange-lemon 
flavour, strawberry flavour, chocolate, peppermint oil, 
double distilled eucalyptol, anethol, methyl salicylate, 
oil cassia (Gavaskar et al., 2010). In addition to the 
flavouring agents, sweetening agents may also be added 
to provide an acceptable taste. Suitable sweetening agents 
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include sucrose, fructose, glucose, sodium saccharin, 
aspartame (Sharma, Lewis, 2010). Colour is a vital means 
of identification for many pharmaceutical tablets and is 
also usually important for consumer acceptance (Saroha 
et al, 2010).
The recent approaches for taste masking are:
1)  Reduction of drug solubility in saliva, where a bal-
ance between reduced solubility and bioavailability 
must be achieved.
2)  To alter the ability of the drug to interact with taste 
receptor (Jha, Sharma, Surendra, 2008).
MATERIAL AND METHODS 
Material
Granisetron hydrochloride was received as 
research sample from Ajanta Pharma Pvt. Ltd, Mumbai, 
India. Kollicoat®Smartseal 30 D and Kollidon CL 
(crospovidone) procured from BASF India Ltd. Mumbai, 
India. Croscarmellose sodium (Ac-Di-Sol) by FMC India 
Ltd. Banglore, India. Avicel PH 101(Microcrystalline 
cellulose) was supplied by Signet Chemical Corporation 
Pvt. Ltd., Mumbai, India. Aerosil 200 and Magnesium 
stearate were obtained by Evonik Degussa India Pvt. Ltd., 
Mumbai, India and Loba Chemie Pvt. Ltd., Mumbai, India 
respectively. All other chemicals were of analytical grade 
and were used as received.
METHODS
Preliminary studies on screening of plasticizer
Tri ethyl citrate, Polyethylene Glycol 400 (PEG 
400), Propylene Glycol (PG) and Dibutyl Phthalate 
(DBP) are used as a plasticizer in the concentration range 
5-70%, 5-30%, 5-40% and 5-50% respectively in order 
to study their effect on the tensile strength, % elongation 
and folding endurance of matrix type patch prepared by 
using single polymer. 
Physical evaluations of patches
Thickness 
The thickness of prepared patches was measured 
using digital vernier callipus with least count 0.01 mm 
(Mitutoyo, Japan) at three different places and the mean 
value was calculated. 
Tensile strength
The instrument was designed such that it had 
horizontal wooden platform with fixed scale and 
attachments for two clips that holds transdermal patch 
under test. Out of the two clips one was fixed and other 
was movable. Weights were hanged to one end of pulley 
and the other end of pulley was attached with movable 
clip. The wooden platform was fitted such that it would 
not dislocate while the test is running. Three strips of patch 
were cut having 2cm length and 2cm width. The thickness 
and breadth of strips were noted at three sites and average 
value was taken for calculation. The rate of change of 
stress was kept constant with the increment of 0.5g per 2 
minutes. The elongation was observed and the total load 
was used for calculation.
The tensile strength was calculated by using 
following formula:
Tensile Stress (S) = Applied force/Cross sectional area = 
m × g/b × t
where S = tensile strength in Kg/mm2; m = mass in grams; 
g = acceleration due to gravity; b = width of strip in 
centimeters;t = thickness of strip in centimeters.
The strain is change resulting in size of strip after 
the force was applied to its original size. Therefore, the 
strain can be given as,
Strain (E) = Total Elongation/ Original Length = L-L0 / L0
where L = length after force was applied; L0 = original 
length.
Percent elongation
The percent elongation at break was measured by 
formula given below.
Percent Elongation = Total Elongation/Original Length 
× 100 = L-L0 / L0 × 100
where, L = length after force was applied.
Weight variation study 
For weight variation test, 3 films from each batch 
were weighed individually and the average weight was 
calculated. The test was performed to check the uniformity 
of weight and to avoid batch- to- batch variation. 
Folding endurance
Folding endurance of patches was determined by 
repeatedly folding a small strip of film (2cm x 2 cm) at 
the same place till it broke. The number of time the film 
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could be folded at the same place without breaking was 
the folding endurance value. 
Method of preparation of granisetron pellets
Granisetron Hydrochloride and other ingredients 
i.e MCC PH 101(70% w/w) and Lactose (30%w/w) were 
mixed properly in a mortar according to compositions. 
The resulting mixture or blend was passed through sieve 
(40#). This blend was granulate with water as binder to 
form dump mass which were extrude and spheronise (R & 
D Extruder & Spheronizer, Anish Pharma, Nashik, India) 
to form pellets of required size.
Coating of pellets with kollicoat smartseal 30 D
Pellets of required size were used for the coating. 
Kollicoat Smartseal 30D disperse in water along with 
talc, colorant and plasticizer of required amount on dried 
basis. The dispersion was allowed to stir for 2h obtain a 
homogeneous dispersion and finally pass through 200 µm 
sieve. The coating dispersion was then layered onto the 
core pellets in Fluidized bed processor (APCG Series Fluid 
Bed Processor Anish Pharma, Nashik, India). The coated 
pellets were further dried in the dryer for 15 min at 40 ̊C 
after the coating process was finished.
Curing of pellets
Immediately after the coating process the coated 
pellets were oven-cured at temperatures 40° and 65°C for 
the 24 hours. Additionally, samples of coated but uncured 
pellets were prepared.
Evaluation of pellets
Prepared pellets were evaluated for different physical 
parameters like moisture content, drug content, shape, angle 
of repose, bulk density, tapped density, compressibility 
index, Hausner ratio. The pellets size was measured under 
compound microscope (Metzer, India) at 10X magnification 
for shape deter mination. Drug content of pellets was 
determined by U.V spectrophotometer at 244 nm. In-vitro 
disintegration time was measured by dropping a little 
quantity of the pellets in a measuring cylinder containing 6 
ml of simulated salivary fluid of pH 6.8. Moisture content 
of pellets was measured using halogen moisture analyzer 
(MB50C, Citizen Scale India Pvt. Ltd., Mumbai, India) at 
105 °C. Angle of repose was measured using fixed funnel 
method. A funnel with 10 mm inner diameter of stem was 
fixed at a height of 2.5 cm over the platform. About 10 g 
of sample was slowly passed along the wall of funnel till 
the tip of the pile formed touches the stem of the funnel. 
A circle was drawn around the pile base and the radius of 
cone was measured. Angle of repose was calculated from 
three averages using formula, q = tan-1(Height/Radius). 
Bulk and tapped density determinations were carried out 
as per method (Method II) described in United States 
Pharmacopoeia (USP) 24.
Formulation of granisetron hydrochloride orally 
dispersible release tablets
Granisetron Hydrochloride coated pellets and Micro 
crystalline cellulose (MCC PH 200) were mixed with 
different disintegrant in a mortar according to compositions 
given in Table I. The three different disintegrants at varying 
levels were used for the preparation of ODT tablets. 
Desired quantity of lubricated blend was weighed and 
fed manually to a pilot press tablet compression machine 
(Chamunda Pharma Machinery Pvt. Ltd.) and compressed 
using 6 mm flat faced round shaped punches at a weight 
of 138 mg. By direct compression method. Compression 
force was kept constant for all formulations.
Evaluation of granisetron hydrochloride orally 
dispersible tablets
Granisetron Hydrochloride tablets were evaluated 
for post compression parameters like hardness, weight 
variation, thickness, friability, disintegration time, drug 
content and in vitro drug release.
Hardness test
Tablets require a certain amount of strength or 
hardness and resistance to withstand mechanical shock 
of handling in manufacture, packing and shipping. To 
perform this test tablets were placed between two anvils, 
force to the anvils and the crushing strength that just causes 
the tablets to break was recorded. Monsanto hardness 
tester was used to measure the hardness of tablets. The 
results were expressed in kg/cm2.
Thickness
The thickness of a tablet is only dimensional variable 
related to the compression process. The thickness of the 
tablets was determined by the Digital Vernier Caliper 
instrument. Ten tablets were used for the determination 
of thickness from each batch. Results were expressed in 
millimeter (mm).
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Friability test
The friability (%) of tablets was determined by using 
Roche type friability testing apparatus. The tablets were 
subjected to the combined effect of abrasion and shock 
by utilizing a plastic chamber that revolves at 25 rpm, 
dropping the tablets at a distance of six inch with each 
revolution. Twenty tablets were weighed and placed in the 
Roche friability test apparatus. After 100 revolutions, the 
tablets were dedusted and weighed again. The friability 
was determined as the percent loss in weight of the tablets. 
   Friability (5) = 1 – × 100
Weight of tablets
after 100 revolutions
Initial weight of tablets
 
The acceptable % friability limit of conventional 
compressed tablet is 0.5 to 1.0 % (USP 2000). 
Dispersion time (Bhardwaj et al., 2010)
In vitro dispersion time was measured by dropping 
a tablet in a 10 ml measuring cylinder containing 6 ml of 
buffer solution simulating saliva fluid (pH 6.8)
Wetting time (Hindustan et al., 2010)
The wetting time of the tablet was measured using 
simple procedure. Five circular tissue paper of 10 cm 
diameter were placed in petridish with 10 cm diameter. Ten 
milliliter of water containing eosin a water soluble dye, 
was added to the petri dish. A tablet was carefully placed 
on the surface of tissue paper. The time required for water 
to reach upper surface of tablet was noted as wetting time. 
Wetting volume (Hindustan et al., 2010)
The tablet is placed in center of petridish and with 
the help of 5 mL pipette distilled water was added drop 
wise on the tablet. The volume required to completely 
disintegrate the tablet was noted as wetting volume.
Water absorption ratio (R) (Battu et al., 2007)
The weight of the tablet prior to placement in the 
Petri dish was noted (Wb) utilizing a digital balance. The 
wetted tablet was removed and reweighed (Wa). Water 
absorption ratio, R, was then determined according to the 
following equation. Where Wb and Wa were tablet weights 
before and after water absorption, respectively. 
R = × 100
(Wb – Wa)
Wa
Disintegration test
Six tablets were selected randomly from each 
batch for the disintegration test. Disintegration test 
was performed in purified water using Electro lab 
Disintegration tester. Disintegration time (DT) was 
measured for all tablets and expressed as Mean ± SD.
In vitro drug release study
The USP type II dissolution apparatus (Electro lab, 
India) were used for dissolution having media of pH 1.2 
HCl buffer with 900 ml volume and rotation speed of 
50rpm. 10 mL sample was withdrawn at predetermined 
time intervals and replaced with same dissolution 
TABLE I - Compositions of orally dispersible tablet (138 mg)
Sr. No. Ingredients(mg) C1 C2 C3 C4 C5 C6
1 Granisetron Hydrochloride 50 50 50 50 50 50
2 MCC PH 200 55 52.5 55 52.5 55 52.5
3 Sodium starch glycolate 5.0 7.5 - - -
4 Cross carmellose sodium - - 5.0 7.5 - -
5 Crospovidon - - - - 5.0 7.5
6 Mannitol NF (Pearlitol SD200) 20.0 20.0 20.0 20.0 20.0 20.0
7 Aspartame 2.0 2.0 2.0 2.0 2.0 2.0
8 Peppermint Flavor 2.5 2.5 2.5 2.5 2.5 2.5
9 Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5
10 Aerosil (Colloidal silicon dioxide) 2.0 2.0 2.0 2.0 2.0 2.0
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media. The withdrawn samples were diluted 100 times, 
filtered and analyzed by using UV spectrophotometer at 
λmax 263 nm of granisetron hydrochloride. This test was 
performed on 3 tablets and mean ± SD was calculated. The 
amount of drug release was determined using calibration 
curve.
Taste evaluation study
The objective of this study is to conduct and 
evaluate the palatability of granisetron hydrochloride oral 
disintegrating tablets. Reference product is not available 
in market for comparison of the taste evaluation study. 
Total eight formulations were selected for taste evaluation 
study, six test formulations, one positive control (Placebo 
for drug) and one is negative control (Placebo for Taste 
enhancers like aspartame and peppermint flavor). All 
formulation batches (C1- C6) were randomized. Each 
randomization order was assigned with sequence code. 
For this study we have selected five healthy human male 
volunteers and were assigned volunteer code.
Stability studies
The stability studies were performed on the 
optimized formulation batches to check the effect of 
environmental or storage conditions. Optimized batch C6 
was kept in environmental stability chamber (Remi Lab, 
Bombay) for accelerated stability condition at 40oC ± 2oC 
temperature and 75 ± 5% relative humidity for a period 3 
months. The samples were withdrawn at end of 1, 2 and 
3 months interval and evaluated for physical parameters, 
drug content and in-vitro drug release
RESULT AND DISCUSSION
After studying the effect of triethyl citrate, 
polyethylene glycol 400, propylene glycol and dibutyl 
phthalate as plasticizers on tensile strength, % elongation 
and folding endurance of matrix type patch prepared 
by casting on mercury base, good results obtained with 
triethyl citrate with respect to percent elongation as 
shown in Table II which help the pellet to withstand in 
stress condition during compression. Also SEM image of 
the compressed tablet with different plastisizer revel that 
triethyl citrate having good plasticizing effect shows no 
rupture under compression as compared to other plastisizer 
as shown in Figure 1 and 2.
Angle of repose is less than 30° suggesting that 
pellets have good flowability. Bulk density is an indication 
of packing properties of material. Variations in the 
bulk density can cause change in fill volume. The bulk 
density of the pellets depends primarily on particle size 
TABLE II - Evaluation of patches prepared by using single polymer containing optimized concentration of different plasticizer
Sr. No. Type of Plasticizer
% w/w of 
Kollicoat 
Smartseal 30D
Thickness 
(mm)
Tensile Strength 
Kg/mm2 % Elongation
Folding 
Endurance 
(No. of times)
1 Tri Ethyl Citrate 20  6.0  10.8746 77.93% 259
2 Di butyl Pthalate 20  6.2  11.0652 69.26% 220
3 Propylene Glycol 20  6.0  10.823 68.15% 205
4 Poly ethylene Glycol 400 20  6.1  10.7054 65.17% 195
FIGURE 1 - SEM Image of Cross-sections of tablet using PEG 
400 as plasticizer.
FIGURE 2 - SEM Image of Cross-sections of tablet using TEC 
as plasticizer.
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distribution, particle shape and frequency of particles to 
adhere together. The particles may pack in such a way so 
as to leave large gaps between their surfaces resulting in 
a light powder of low bulk density. On the other hand, the 
smaller particles may pack between the larger ones to form 
a heavy powder or one of high bulk density. It has been 
reported that bulk density less than 1.25 g/cm3 indicates 
good flowability. It is evident from table that pellets with 
all the batches have bulk density in the range 0.3-0.5 g/
cm3. Carr’s index (CI) is an important measure that can 
be obtained from the bulk and tapped densities. The less 
compressible a material the more flowable it is. Hausner’s 
ratio is the ratio of tapped density and bulk density and 
is related to interparticle friction and, as such, could be 
used to predict powder flow properties. Generally a value 
less than 1.25 indicates good flow properties, which is 
equivalent to 10% of Carr’s index.When compressibility 
ranges from 5 to 16 and Hausner’s ratio closer to 1.25, 
the materials have acceptable flow property and packing 
ability. All pellets have shown good compression 
properties as shown in Table III.
The compressed tablets were evaluated for weight 
variation, thickness hardness, friability, disintegration and 
drug content. All the weights were within ± 5% deviation 
range and passed the weight variation test according to 
USP. The hardness of the tablets was found to be about 
3.0 – 4.0 kg/cm2. Friability index is a measure of integrity 
of the material, which is a function of cohesiveness. It 
is an indication of endurance of material during various 
operations like packaging, transportation and handling. 
The generally agreed upper limit for friability is 1%. The 
friability of the tablets was found within the desirable range 
0.1- 0.3%, hence the tablets passed the friability. Wetting 
time was determined for all of the formulations. Wetting 
time of all the formulation was more than 30 sec, except 
C6 (7.5% w/w) having the wetting time 24 sec was less 
compared to all formulations due to its rapid water absorbing 
nature involving both capillary and swelling mechanisms 
of crospovidone. Water absorption ratio ‘R’ increased 
with an increase in superdisintegrants’ concentrations 
from 5 - 10 %. A linear relationship was observed for each 
of the superdisintegrant types. The increase in ‘R’ was 
most likely due to increased water uptake capacity of the 
superdisintegrants at higher concentrations. The tablets 
were assayed and the drug content was found to be in the 
range of 90-110 % as per USP standards. Disintegration time 
(DT) stands satisfactory with the time limit of <1 min for 
all the batches, as shown in Table IV. However DT of batch 
no. C6 found to be 22 sec which was lowest as compared to 
other formulations. It is considered that the disintegration 
is the first step in the dissolution of immediate release 
tablets. The lower the disintegration time, higher the rate 
of dissolution Hence, for the comparative study, one with 
the same percentage was selected (5%).
TABLE III - Evaluation of Flow properties of coated pellets with Kollicoat® Smartseal 30D D with triethyl citrate as plasticizer 
(Mean ± SD) (Three number each of C1- C6, n=3)
Test C1 C2 C3 C4 C5 C6
Angle of repose (°) 26.67±0.33 29.68±0.57 27.32±0.61 27.63±0.51 26.42±0.43 28.51±0.38
Bulk density (g/mL) 0.39±0.025 0.38±0.052 0.38±0.024 0.38±0.035 0.38±0.062 0.38±0.058
Tapped Density (g/ml) 0.44±0.084 0.44±0.012 0.44±0.032 0.44±0.021 0.44±0.039 0.44±0.085
Carr’s index 11.11±0.057 11.15±0.022 11.10±0.011 11.13±0.053 11.15±0.020 11.11±0.018
Hausner’s ratio 1.125±0.034 1.210±0.043 1.120±0.010 1.126±0.008 1.212±0.034 1.112±0.031
TABLE IV - Different evaluation parameters of granisetron hydrochloride ODT tablets (mean ± SD) n=3
Test C1 C2 C3 C4 C5 C6
Hardness (Kg/cm²) 3.5± 0.5 4.0± 0.5 4.5± 0.5 3.5± 0.5 4.0± 0.5 3.0± 0.5
Friability (%) 0.2 ± 0.004 0.13 ± 0.014 0.14 ± 0.008 0.13 ± 0.007 0.22 ± 0.009 0.21 ± 0.011
Thickness (mm) 4.38 ± 0.40 4.31± 0.45 4.39 ± 0.25 4.37 ± 0.48 4.39 ± 0.14 4.34 ± 0.64
Drug content (%) 97.24 ± 0.24 97.36 ± 0.81 98.20 ± 0.53 97.52 ± 0.82 99.20 ± 0.79 98.62 ± 0.61
Weight variation (%) 3.75 ± 0.20 3.26 ± 0.30 3.49 ± 0.26 4.56 ± 0.60 3.48 ± 0.40 4.64 ± 0.30
Disintegration (in sec) 35 ± 1.0 30 ± 1.0 32± 1.0 28 ± 2.0 28 ± 1.0 22 ± 1.0
Wetting time (in sec) 37± 1.0 33± 1.0 34± 1.0 31± 1.0 31± 1.0 24± 1.0
Water absorption ratio 148 178 120 132 95 105
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In vitro drug release studies of granisetron 
hydrochloride ODT tablets
Drug release of C1-C6 batch containing various 
superdisintegrants in different concentration of 5 and 7.5% 
w/w was compared, it was found that C6 batch containing 
Crospovidon releases drug more promptly and completely 
within 30 min. Hence, C6 batch is considered as optimized 
batch for granisetron hydrochloride orodispersible tablets 
as shown in Figure 3.
The results shown in Table V indicate that all 
the prepared formulation were similar in terms of 
patient acceptability, it was observed in prepared 
formulations using peppermint flavor, mannitol as a flavor 
enhancing agent, aspartame as a taste enhancing agents 
are responsible for good acceptability by the volunteers.
Stability study
Stabi l i ty  tes t ing on opt imized batches  of 
orodispersible tablets as per ICH guidelines was carried 
out. After checking the parameters, no significant change 
was found in all the batches before and after stability study. 
The results obtained as shown in Table VI. The in vitro 
drug release study of optimised batch C6 was carried out 
and no significant changes were found in release patter of 
drug as shown in Figure 4.
CONCLUSION
Taste masked orally disintegrating granisetron 
TABLE V - Summary report of taste evaluation study report
Formulation Average point by individual Acceptability Rank
Positive control 98 Very Good 1
C1 95 Very Good 3
C2 91 Very Good 6
C3 94 Very Good 4
C4 90 Very Good 7
C5 97 Very Good 2
C6 92 Very Good 5
Negative control 11 Worst 8
Scale range: 81-100 – Very Good, 71-80 – Good, 61 – 70 – Acceptable, 41-60 – Poor, 11-40 – worst and 0-10 – not tolerable
FIGURE 3 - Effect of different Superdisintegrant Sodium starch 
glycolate(C1 & C2), cross carmellose sodium (C3 & C4) and 
crospovidone (C5 & C6)in different concentration (5% & 7.5%) 
on in vitro release of granisetron hydrochloride (n = 3, mean ± SD).
TABLE VI - Evaluation parameters of stability batch (C6)
Evaluation parameters Before stability storage
After1 month 
storage
After2 months 
storage
After3 months 
storage
Hardness (kg/cm2) 3.0 ± 0.4 3.0 ± 0.6 2.5 ± 0.6 2.5 ± 0.8
Friability (%) 0.21 ± 0.06 0.23 ± 0.06 0.26 ± 0.03 0.26 ± 0.04
Weight variation (%) 4.64 ± 0.30 4.67± 0.50 4.70± 0.43 4.69± 0.35
Drug content (%) 98.62 ± 0.61 97.64 ± 1.3 96.89 ± 1.5 96.18 ± 1.9
% drug release of at the end of 30 min 99.75±1.5 98.98 ± 1.4 97.97 ± 2.2 97.59 ± 1.9
The data are presented as mean value ± S.D. (n = 3)
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hydrochloride tablets were formulated for more palatable 
and compliance disin tegration in oral cavity. By using 
Kollicoat® Smartseal 30D masked effectively bitter taste 
of granisetron hydrochloride. Triethyl citrate was found 
to be the best plasticiser having high flexibility with no 
rupture during compression of pellets. The formula tions 
containing Crospovidon as disintegrant have shown tablets 
with desired physical parameters and about 93% of drug 
was released within 10 minutes when used at 7.5% w/w 
level. The formulation of Granisetron hydrochloride orally 
disintegrating tablet was successfully developed with 
following attributes,
·	 Rapid Disintegration in mouth 
·	 Desired Dissolution Profile 
·	 Taste mask with smoother mouth feel 
·	 Stable and robust formulation 
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